The transition from mild to moderate-to-severe chronic plaque psoriasis

被引：0
|
作者：
Bellinato, Francesco [1 ,3 ]
Gisondi, Paolo [1 ]
Mioso, Guido [2 ]
Mason, Elena [1 ]
Straiotto, Danny [2 ]
Piaserico, Stefano [2 ]
Girolomoni, Giampiero [1 ]
机构：
[1] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy
[2] Univ Padua, Dept Med, Sect Dermatol, Padua, Italy
[3] Univ Verona, Dept Med, Sect Dermatol & Venereol, Piazzale A Stefani 1, I-37126 Verona, Italy
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 10期
关键词：
LATE-ONSET;
D O I：
10.1111/jdv.19208
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E1215 / E1217
页数：3
相关论文
共 50 条
  • [41] Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis
    Leman, J.
    Burden, A. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 12 - 20
  • [42] Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis
    Bianchi, Luca
    Del Duca, Ester
    Romanelli, Marco
    Saraceno, Rosita
    Chimenti, Sergio
    Chiricozzi, Andrea
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (09) : 1121 - 1128
  • [43] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium
    Carmona-Rocha, Elena
    Puig, Lluis
    IMMUNOTHERAPY, 2023, 15 (15) : 1209 - 1225
  • [44] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Gordon, K. B.
    Blauvelt, A.
    Papp, K. A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Reich, K.
    Amato, D.
    Ball, S. G.
    Braun, D. K.
    Cameron, G. S.
    Erickson, J.
    Konrad, R. J.
    Muram, T. M.
    Nickoloff, B. J.
    Osuntokun, O. O.
    Secrest, R. J.
    Zhao, F.
    Mallbris, L.
    Leonardi, C. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
  • [45] NEW INJECTABLE DRUG TREATS MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2017, 117 (06) : 23 - 23
  • [46] Apremilast in moderate-to-severe plaque psoriasis (ESTEEM 2 trial)
    Anstey, Alex
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) : E23 - E23
  • [47] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Egeberg, Alexander
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2101 - 2102
  • [48] Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
    Ren, Vicky
    Dao, Harry, Jr.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2013, 6 : 75 - 80
  • [49] Epidemiology of Moderate-to-Severe Plaque Psoriasis in a Canadian Surveyed Population
    Papp, Kim
    Valenzuela, Fernando
    Poulin, Yves
    Bernstein, Geula
    Wasel, Norman
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2010, 14 (04) : 167 - 174
  • [50] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
12345